Oxford Biomedica (LON:OXB) Issues Earnings Results

Oxford Biomedica (LON:OXB) issued its earnings results on Wednesday. The biopharmaceutical company reported GBX (41.75) (($0.54)) EPS for the quarter, Digital Look Earnings reports. Oxford Biomedica had a negative net margin of 145.98% and a negative return on equity of 202.50%.

Oxford Biomedica Trading Down 1.8 %

LON OXB opened at GBX 273.50 ($3.55) on Friday. The company has a quick ratio of 1.67, a current ratio of 2.35 and a debt-to-equity ratio of 166.48. Oxford Biomedica has a 52 week low of GBX 187.83 ($2.44) and a 52 week high of GBX 455 ($5.91). The business has a 50 day moving average price of GBX 319.38 and a 200-day moving average price of GBX 379.08. The company has a market cap of £290.73 million, a price-to-earnings ratio of -2.03 and a beta of 1.09.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies.